Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Complement c5 inhibitors
10 evidence topics · 6 sources
Avacincaptad pegol: indication, dosage, and contraindications
Avacincaptad pegol: neovascular AMD and intraocular pressure warnings
GATHER1 and GATHER2: design
GATHER1 and GATHER2: GA growth with monthly dosing
| Study and time point | Avacincaptad pegol, N | Sham, N | GA rate of growth, avacincaptad pegol (mm2/year) | GA rate of growth, sham (mm2/year) | Difference (95% CI) (mm2/year) | Difference % | p value |
|---|---|---|---|---|---|---|---|
| GATHER1, month 12 | “N=67” | “N=110” | “1.22” | “1.89” | “0.67 (0.21-1.13)” | “35%” | “<0.01” |
| GATHER2, month 12 | “N=225” | “N=222” | “1.75” | “2.12” | “0.38 (0.12-0.63)” | “18%” | “<0.01” |
| GATHER2, month 24 (monthly in both years) | “N=96” | “N=203” | “2.23” | “2.59” | “0.36 (0.07 – 0.66)” | “14%” | “0.0165” |
GATHER1: phase 2/3 primary endpoint
“A total of 286 participants with GA secondary to AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The reduction in the mean rate of GA growth (square root transformation) over 12 months was 27.4% (P = 0.0072) for the avacincaptad pegol 2 mg cohort and 27.8% (P = 0.0051) for the avacincaptad pegol 4 mg cohort compared with their corresponding sham cohorts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GATHER2: 12-month primary endpoint and safety
“To be eligible, patients had to be aged 50 years or older with non-centrepoint-involving geographic atrophy and best corrected visual acuity between 20/25 and 20/320 in the study eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between June 22, 2020, and July 23, 2021, 1422 patients were screened for eligibility, of whom 448 were enrolled and randomly assigned to avacincaptad pegol 2 mg (n=225) or sham (n=223).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“representing a 14% difference between the avacincaptad pegol 2 mg group and the sham group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were no endophthalmitis, intraocular inflammation, or ischaemic optic neuropathy events over 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To month 12, macular neovascularisation in the study eye occurred in 15 (7%) patients in the avacincaptad pegol 2 mg group and nine (4%) in the sham group, with exudative macular neovascularisation occurring in 11 (5%) in the avacincaptad pegol 2 mg group and seven (3%) in the sham group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GATHER2: two-year results
“Overall, 175 and 184 patients in the ACP and sham group completed the study at year 2, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From baseline to year 2, the mean rate of GA area growth was 4.46 mm2 (standard error [SE], 0.25 mm2) with ACP EM and 5.18 mm2 (SE, 0.17 mm2) with sham, a difference in growth of 0.724 mm2 (95% confidence interval [CI], 0.133-1.315 mm2; P = 0.0165), representing a 14% difference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of choroidal neovascularization (study eye) was 11.6% with ACP (all treated) versus 9.0% with sham over 2 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No events of retinal vasculitis, ischemic optic neuropathy, or serious intraocular inflammation occurred over 2 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GATHER2: guideline summary of lesion growth reductions
GATHER1 and GATHER2: post hoc analysis of vision loss
“A post hoc analysis of 12-month data for pooled ACP 2 mg and sham groups is reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lower proportions of study eyes experienced ≥10-, ≥15-, or ≥20-BCVA letter loss from baseline over 12 months with ACP 2 mg (11.6%, 4.0%, and 1.6%, respectively) versus sham (14.1%, 7.6%, and 4.5%, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was a reduction in the risk of persistent loss of ≥15 BCVA ETDRS letters with ACP 2 mg (3.4%) versus sham (7.8%) through 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote